Anavex Life Sciences Reports Fiscal 2024 First Quarter

Company to host a webcasttoday at 8:30 a.m. Eastern TimeNEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the ...

Related Keywords

United States , Christopheru Missling , Andrewj Barwicki , Union Marketing Authorisation , European Medicines Agency , Nasdaq , Anavex Life Sciences Corp , Committee For Medicinal Products Human Use , European Union , Instagram , Muscarinic Receptor Agonist In Development , Company On Twitter , Compassionate Use Program , Research Business Development , Facebook , Michaelj Fox Foundation For Parkinson Research , Linkedin , Clinical Pharmacology In Drug Development , European Brain Council , Trademark Office , Company Nasdaq , Life Sciences , Marketing Authorisation , Chief Executive Officer , Pipeline Updates , European Brain , Business Highlights , Clinical Pharmacology , Drug Development , Population Based Characterization , Food Effect , Receptor Agonist , Frontotemporal Dementia , United States Patent , Real World Evidence , Compassionate Use , Medicinal Products , Human Use , Marketing Authorisation Application , Based Characterization , Clin Pharmacol Drug , Conference Call Information , Annual Report , Anavex Life Sciences , Consolidated Interim Statements , Further Information ,